Dave Gennert, PhD
@davegennert.bsky.social
Genetics & bio nerd | science communications & writing | Science pubs @ Insilico Medicine | recovering journal editor | uses "wicked" as an adverb | posts & opinions my own
Super proud of our new paper out in Nature Medicine @natureportfolio.nature.com: Phase IIa trial of AI-discovered #Rentosertib in ptns w/ IPF. Absolute privilege working w/ amazing Insilico clinical & science teams & collabs. Many thnx to ptns for their trust!
www.nature.com/articles/s41...
www.nature.com/articles/s41...
A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial - Nature Medicine
Preliminary results from a phase 2a trial involving 71 patients suggest that a new agent, discovered and designed with artificial intelligence assistance, is safe and effective for the treatment of id...
www.nature.com
June 4, 2025 at 1:47 PM
Super proud of our new paper out in Nature Medicine @natureportfolio.nature.com: Phase IIa trial of AI-discovered #Rentosertib in ptns w/ IPF. Absolute privilege working w/ amazing Insilico clinical & science teams & collabs. Many thnx to ptns for their trust!
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Reposted by Dave Gennert, PhD
The first generative AI drug to get to a Phase 2 randomized clinical trial. The small molecule in pill form, rentosertib, showed signs of efficacy for idiopathic pulmonary fibrosis @naturemedicine.bsky.social
www.nature.com/articles/s41...
www.nature.com/articles/s41...
June 3, 2025 at 1:03 PM
The first generative AI drug to get to a Phase 2 randomized clinical trial. The small molecule in pill form, rentosertib, showed signs of efficacy for idiopathic pulmonary fibrosis @naturemedicine.bsky.social
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Hi! Super excited to start out here with a lil' bragging. New paper out now in @naturebiotech.bsky.social from #InsilicoMedicine w/ #drugdiscovery of ISM012-042, a gut-restricted PHD1/2 inhibitor for treating #IBD. Target & molecule discovered via #AI. Now in Phase 1!
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Intestinal mucosal barrier repair and immune regulation with an AI-developed gut-restricted PHD inhibitor - Nature Biotechnology
Generative artificial intelligence is used to design an effective treatment for inflammatory bowel disease in preclinical models.
www.nature.com
December 12, 2024 at 4:53 PM
Hi! Super excited to start out here with a lil' bragging. New paper out now in @naturebiotech.bsky.social from #InsilicoMedicine w/ #drugdiscovery of ISM012-042, a gut-restricted PHD1/2 inhibitor for treating #IBD. Target & molecule discovered via #AI. Now in Phase 1!
www.nature.com/articles/s41...
www.nature.com/articles/s41...